Displaying 121 - 140 of 853
| Active Ingredient | HYDROXYCHLOROQUINE |
| Therapeutic Class | ANTIMALARIALS |
| Indications | Used in both the treatment and sup p ression of malaria, as well for the treatment of rheumatoid arthritis and sy stemic lup us ery thematosus. |
| Caution |
Adverse effects following short -term therap y include rash, vertigo, transient headache and gastrointestinal comp laints such as nausea, vomiting, diarrhea and abdominal cramps. Ocular to More ... |
| Dose Range | Lupus: Initially , 400mg 1-2 times daily until remission. Maintenance: 200-400mg daily . Take with food or milk. |
| Drug Interactions | Healthcare professionals are reminded to consider the benefits and risks of co-prescribing systemic azithromycin, or other systemic macrolides, with hydroxychloroquine, if this cannot be avoided , pat More ... |
| Pregnancy | It is not necessary to withdraw an antimalarial drug during pregnancy if the rhe More ... |
| Breast Feeding | It is advised to avoid due to the potential risk of toxicity in the infant. moni More ... |
| Active Ingredient | MEFLOQUINE |
| Therapeutic Class | ANTIMALARIALS |
| Indications | Mefloquine is indicated for the prophylaxis and the treatment of mild to moderate malaria caused by Plasmodium vivax and susceptible strains of Plasmodium falciparum. |
| Caution | Anorexia, vomiting, nausea, diarrhoea, dizziness ,sleep disturbance, panic attacks, sudden on set of anxiety , restlessness, irritability, confusion, persistently abnormal heart beat, palpitations, b More ... |
| Dose Range | Acute disease: 5 tablets (1250mg) should be given as a single oral dose or 750mg initially followed by 500mg given 12 hours later. Prophylaxis: 250mg per week prior to departure (commence 1-3weeks prior to travel), during period in endemic area and 4 weeks after return. Alternatively : 250mg for 3 days followed by 250mg weekly (in cases where a loading dose is required). (NB: 250mg M efloquine HCL = 228mg of the base). |
| Drug Interactions | When mefloquine is used for prevention or chemoprophylaxis of malaria in travelers, possible effects of mefloquine on other drugs these individuals are receiving (especially anticoagulants and antidia More ... |
| Pregnancy | Manufacturer advises avoid unless the potential benefit outweighs the risk parti More ... |
| Breast Feeding | Present in milk but risk to infant minimal. |
| Active Ingredient | PRIMAQUINE PHOSPHATE |
| Therapeutic Class | ANTIMALARIALS |
| Indications | Malaria. Used with chloroquine. |
| Caution | To decrease G.I. side effects. Monitor for hematological effects. |
| Dose Range | 15mg (base) daily for 14 day s. M ay be used for up to 21 day s. Take with food. |
| Drug Interactions | |
| Pregnancy | The manufacturer states that primaquine should be avoided during pregnancy. Risk More ... |
| Breast Feeding |
| Active Ingredient | QUININE BISULPHATE |
| Therapeutic Class | ANTIMALARIALS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | QUININE DIHYDROCHLORIDE |
| Therapeutic Class | ANTIMALARIALS |
| Indications | Malaria. |
| Caution | Phototoxicity , ototoxicity , drug fever. |
| Dose Range | Adult: 600mg every 8 hours for 7 days. Pediatric: 10mg/kg 3 times daily for 7 days. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | QUININE SULPHATE |
| Therapeutic Class | ANTIPROTOZOALS |
| Indications | Malaria. |
| Caution | Phototoxicity, ototoxicity, drug fever. |
| Dose Range | Adult: 600mg every 8 hours for 7 days. Pediatric: 10mg/kg 3 times daily for 7 days. |
| Drug Interactions | |
| Pregnancy | The manufacturers state that quinine should be used during pregnancy only if the More ... |
| Breast Feeding | Although quinine generally is considered compatible with breast-feeding, the ris More ... |
| Active Ingredient | METRONIDAZOLE |
| Therapeutic Class | ANTIPROTOZOALS, MISCELLANEOUS |
| Indications |
Metronidazole is an antimicrobial drug with high activity against anaerobic bacteria and protozoa. Trichomonas vaginalis. Giardia lambia, Entamoeba histolytica. Active against anaerobic bacteria and More ... |
| Caution |
May be taken with food or milk to avoid stomach upset. May turn urine a reddish-brown colour. For topical use; avoid exposure to strong sunlight or UV light. Common Side effects seen with oral use- More ... |
| Dose Range |
Adult: 400mg every 8 hours for 7 days or 500g every 8 hours ; 800mg in the morning and 1.2g at night; or a single 2g dose. i.v (see category B): Pediatric: 7.5mg/kg every 8 hours. Vaginal gel: One applicatorful once or twice daily for 5 day s. |
| Drug Interactions | Avoid alcohol while taking this drug. The manufacturers recommend that alcohol not be consumed during or for at least 1 day (or at least 3 days with the oral capsules or extended-release oral tablets) More ... |
| Pregnancy |
Use with caution. With systemic use: Manufacturer advises avoidance of high-dos More ... |
| Breast Feeding | Use with caution as therapeutic levels can be found in breastmilk and will produ More ... |
| Active Ingredient | PENTAMIDINE |
| Therapeutic Class | ANTIPROTOZOALS, MISCELLANEOUS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | TINIDAZOLE |
| Therapeutic Class | ANTIPROTOZOALS, MISCELLANEOUS |
| Indications | Anaerobic bacterial and protozoal infections. |
| Caution | See Metronidazole. Avoid alcohol |
| Dose Range | 2g (4 tabs) at one time. Same dose for p artner. Take with food. |
| Drug Interactions | |
| Pregnancy | Avoid in the first trimester of pregnancy. |
| Breast Feeding | Breast-feeding should be interrupted during tinidazole therapy and for 72 hours More ... |
| Active Ingredient | HEXAMINE MANDELATE |
| Therapeutic Class | URINARY ANTI-INFECTIVES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | NITROFURANTOIN |
| Therapeutic Class | URINARY ANTI-INFECTIVES |
| Indications | Urinary tract infections. |
| Caution |
Nausea, vomiting. Avoid antacids. C.f. prescribing in liver and renal disease p . 15; 33. |
| Dose Range | Adult: 50 to 100 mg four times daily for 7 days, or 50-100mg at night for long term suppressive therapy . Pediatric: 3 months and over: 3mg/kg daily in 4 divided doses. Take with food or milk. |
| Drug Interactions | |
| Pregnancy | The drug should be used during pregnancy only when clearly indicated and is con More ... |
| Breast Feeding |
| Active Ingredient | ACTINOMYCIN D |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ANASTROZOLE |
| Therapeutic Class | ANTINEOPLASTICS - Aromatase Inhibitor |
| Indications | Advanced or locally advanced breast cancer, adjuvant treatment in hormone receptor-positive early breast cancer in postmenopausal women. |
| Caution | Gastrointestinal disturbances, hot flushes, dizziness, drowsiness, headache, rash, hair thinning, vaginal dryness or bleeding, myalgia, arthralgia, carpal tunnel syndrome, and bone pain and/or More ... |
| Dose Range | Adult: 1 mg once daily with or without food. |
| Drug Interactions |
Estrogen-containing Therapies Tamoxifen |
| Pregnancy | Avoid in pregnancy. This drug can cause fetal toxicity when administered to preg More ... |
| Breast Feeding | Avoid. |
| Active Ingredient | ANTINEOPLASTICS |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | AZATHIOPRINE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Usually as an adjunct to corticosteroids, in autoimmune disorders, e.g. SLE and rheumatoid arthritis. C.f. prescribing in liver and renal disease p. 11; 23. |
| Caution | leukopenia, infection,abdominal pain, alopecia, diarrhea, fever, rash, bone marrow suppression, myalgia |
| Dose Range | 1-3mg/kg daily , usually 100-200mg daily . Take with food. |
| Drug Interactions | |
| Pregnancy | Azathioprine can cause fetal harm when administered to a pregnant woman.The manu More ... |
| Breast Feeding | Breast feeding has not been recommended in azathioprine therapy because of the p More ... |
| Active Ingredient | BEVACIZUMAB |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | BICALUTAMIDE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Bicalutamide is indicated either alone or as adjuvant to radical prostatectomy or radiotherapy in patients with locally advanced prostate cancer at high risk for disease progression. |
| Caution | Consider periodic liver function tests. Constipation, dyspepsia, flatulence, pruritus, asthenia, alopecia, jaundice, dry skin, hot flashes, gynaecomastia and/or breast pain and photosensitiv More ... |
| Dose Range |
50mg once daily in conjunction with a gonadotropin-releasing hormone (GnRH) analog. 150 mg once a day as monotherapy |
| Drug Interactions |
Bicalutamide is an inhibitor of CYP 3A4, with lesser inhibitory effects on CYP 2C9, 2C19 and 2D6 activity. Caution should be exercised with the co-administration of bicalutamide with compounds such a More ... |
| Pregnancy | Bicalutamide is contraindicated in females and should not be used |
| Breast Feeding | Bicalutamide is contraindicated in females and should not be used during breast- More ... |
| Active Ingredient | BLEOMYCIN SULPHATE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Squamous cell carcinomas. |
| Caution | Extravasation, thromboembolism, nausea, vomiting,stomatitis, fever and chills, alopecia, pulmonary fibrosis. |
| Dose Range |
i.v. i.m: 15 000 IU.3 times a week, or 30 000 IU. Twice a week in combination regimens. This may be repeated, at 3 to 4 weeks intervals, up to a total cumulative dose of 500 000 IU. Dose and total cumulative dose should be reduced in those ov |
| Drug Interactions | |
| Pregnancy | Bleomycin sulfate can cause fetal toxicity when administered to pregnant women. More ... |
| Breast Feeding | Discontinue breastfeeding. |
| Active Ingredient | BUSULPHAN |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Chronic myeloid leukaemia. |
| Caution | Leukopenia, thrombocytopenia, anaemia, amenorrhoea, (occasional), skin hyperpigmentation (occasional), gynecomastia (occasional) Adisonian - like wasting syndrome, pulmonary fibrosis (rare More ... |
| Dose Range |
60 micrograms/kg daily , with a usual maximum single daily dose of 4 mg. Maintenance: 0.5-2mg daily . |
| Drug Interactions | |
| Pregnancy | Busulfan may cause fetal harm when administered to pregnant women, but potential More ... |
| Breast Feeding | Discontinue breast-feeding. |
| Active Ingredient | CAPECITABINE |
| Therapeutic Class | ANTINEOPLASTICS |
| Indications | Metastatic colorectal cancer, locally advanced or metastatic breast cancer after failure of anthracycline-containing chemotherapy. |
| Caution | Diarrhoea (which may be severe), nausea and vomiting, abdominal pain, stomatitis. |
| Dose Range | Initial oral dose 1.25 g/m2 given twice daily . Doses are given for 14 days, followed by a 7-day rest period. |
| Drug Interactions | |
| Pregnancy | Capecitabine may cause fetal harm when administered to pregnant women. Capecitab More ... |
| Breast Feeding | Because of the potential for serious adverse reactions to capecitabine in nursin More ... |